CCIA
VRDN icon

Campbell & Co Investment Adviser’s Viridian Therapeutics VRDN Stock Holding History

Campbell & Co Investment Adviser’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$590K Sell
30,157
-17,695
-37% -$526K 0.03% 692
2025
Q4 		$1.49M Buy
47,852
+21,537
+82% +$591K 0.07% 429
2025
Q3 		$568K Buy
+26,315
New +$475K 0.04% 671

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Campbell & Co Investment Adviser's VRDN Position: Q1 2026 in Review

Campbell & Co Investment Adviser reduced its Viridian Therapeutics (VRDN) stake by 37% in Q1 2026, selling an estimated $526K and leaving 30,157 shares worth $590K. The position accounts for 0.03% of the portfolio, ranked #692.

Campbell & Co Investment Adviser first reported a position in VRDN in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.49M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Campbell & Co Investment Adviser held 30,157 shares of Viridian Therapeutics worth $590K as of Q1 2026.
  • Campbell & Co Investment Adviser sold 17,695 Viridian Therapeutics shares in Q1 2026, an estimated $526K.
  • Viridian Therapeutics made up 0.03% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #692 holding.
  • Campbell & Co Investment Adviser first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Campbell & Co Investment Adviser's Viridian Therapeutics position peaked at $1.49M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.